Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Vaxart, Inc.

VXRT · OTC · CIK 0000072444 · Healthcare · Biotechnology

INSIDER SIGNAL

39.0 / 100

1 buyers · 1 purchase transaction lines · $6.5K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+1.2 / 25
Role+20.0 / 20
Recency+0.8 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Watson W. MarkDirector
●○
BREITMEYER JAMES BDirector
○○
Grasman Jeroen NicolaasChief Financial Officer
○
Finney KevinDirector
○
HERON ELAINE JDirector
○
Wheadon David E.Director
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Watson W. Mark · $6.5K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-05-22–2026-05-22

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

39.0 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 39.1
  2. 39.1
  3. 39.1
  4. 39.1
  5. 39.0

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

5Purchases
0Sales
27Other Form 4 lines
29SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER7 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-12.2%
3M
-20.4%
6M
-31.7%
12M
+26.5%

Volatility & liquidity

Volatility
98.0%
Beta
—
Avg daily value
USD 120,900

Valuation

Market cap
USD 104.4M
P/E
6395.5×

Fundamentals

Profit margin
0.0%
ROE
0.0%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, P/E, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
2,326,956
Previous report
2,306,655
Avg daily volume
499,839
Days to cover
4.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-22Watson W. MarkPurchase (P)Common Stock10,000USD 0.65USD 6,500SEC filing ↗
2025-11-17Watson W. MarkPurchase (P)Common Stock20,000USD 0.41USD 8,200SEC filing ↗
2025-11-17HERON ELAINE JPurchase (P)Common Stock40,000USD 0.40USD 15,936SEC filing ↗
2025-08-15Finney KevinPurchase (P)Common Stock100,000USD 0.36USD 36,000SEC filing ↗
2025-07-30Finney KevinPurchase (P)Common Stock25,874USD 0.38USD 9,832SEC filing ↗
2025-07-29Watson W. MarkPurchase (P)Common Stock10,000USD 0.41USD 4,100SEC filing ↗
2025-07-28Finney KevinPurchase (P)Common Stock20,000USD 0.40USD 8,000SEC filing ↗
2025-07-25Finney KevinPurchase (P)Common Stock20,000USD 0.39USD 7,800SEC filing ↗
2025-07-17Finney KevinPurchase (P)Common Stock794USD 0.38USD 302SEC filing ↗
2025-05-19Lo StevenPurchase (P)Common Stock100,000USD 0.49USD 49,000SEC filing ↗
2024-06-18Watson W. MarkPurchase (P)Common Stock20,000USD 0.68USD 13,600SEC filing ↗
2022-12-28Watson W. MarkPurchase (P)Common Stock20,000USD 0.76USD 15,200SEC filing ↗
2022-06-22Ahmad FuadPurchase (P)Common Stock5,000USD 3.22USD 16,100SEC filing ↗

Form 4 evidence

32 transaction lines in the latest 365-day window; 219 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-16Finney KevinAward / grant (A)Common Stock39,400USD 0.00USD 0SEC filing ↗
2026-07-16Wheadon David E.Award / grant (A)Common Stock39,400USD 0.00USD 0SEC filing ↗
2026-07-16Watson W. MarkAward / grant (A)Common Stock39,400USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-16Finney KevinAward / grant (A)Common Stock39,400USD 0.00USD 0SEC filing ↗
2026-07-16Wheadon David E.Award / grant (A)Common Stock39,400USD 0.00USD 0SEC filing ↗
2026-07-16Watson W. MarkAward / grant (A)Common Stock39,400USD 0.00USD 0SEC filing ↗
2026-07-16HERON ELAINE JAward / grant (A)Common Stock39,400USD 0.00USD 0SEC filing ↗
2026-07-16BREITMEYER JAMES BAward / grant (A)Common Stock8,315USD 0.00USD 0SEC filing ↗
2026-05-22Watson W. MarkPurchase (P)Common Stock10,000USD 0.65USD 6,500SEC filing ↗
2026-05-19Grasman Jeroen NicolaasTax withholding (F)Common Stock31,395USD 0.61USD 19,151SEC filing ↗
2026-04-23BREITMEYER JAMES BAward / grant (A)Common Stock78,800USD 0.00USD 0SEC filing ↗
2026-03-28Tucker SeanTax withholding (F)Common Stock3,924USD 0.65USD 2,551SEC filing ↗
2026-03-28Cummings James F.Tax withholding (F)Common Stock3,292USD 0.65USD 2,140SEC filing ↗
2026-03-24Tucker SeanTax withholding (F)Common Stock36,418USD 0.69USD 25,128SEC filing ↗
2026-03-24Lo StevenTax withholding (F)Common Stock126,028USD 0.69USD 86,959SEC filing ↗
2026-03-24Cummings James F.Tax withholding (F)Common Stock30,551USD 0.69USD 21,080SEC filing ↗
2026-03-24Berg Edward BTax withholding (F)Common Stock36,418USD 0.69USD 25,128SEC filing ↗
2026-03-18Tucker SeanTax withholding (F)Common Stock8,072USD 0.63USD 5,085SEC filing ↗
2026-03-18Lo StevenTax withholding (F)Common Stock22,425USD 0.63USD 14,128SEC filing ↗
2026-03-18Cummings James F.Tax withholding (F)Common Stock6,772USD 0.63USD 4,266SEC filing ↗
2026-03-18Berg Edward BTax withholding (F)Common Stock8,072USD 0.63USD 5,085SEC filing ↗
2026-03-16Tucker SeanAward / grant (A)Common Stock200,000USD 0.00USD 0SEC filing ↗
2026-03-16Lo StevenAward / grant (A)Common Stock846,500USD 0.00USD 0SEC filing ↗
2026-03-16Grasman Jeroen NicolaasAward / grant (A)Common Stock227,000USD 0.00USD 0SEC filing ↗
2026-03-16Cummings James F.Award / grant (A)Common Stock227,000USD 0.00USD 0SEC filing ↗
2026-03-16Berg Edward BAward / grant (A)Common Stock115,000USD 0.00USD 0SEC filing ↗
2026-02-02Tucker SeanTax withholding (F)Common Stock9,265USD 0.61USD 5,652SEC filing ↗
2026-02-02Cummings James F.Tax withholding (F)Common Stock7,965USD 0.61USD 4,859SEC filing ↗
2026-02-02Berg Edward BTax withholding (F)Common Stock9,265USD 0.61USD 5,652SEC filing ↗
2025-12-04Lo StevenTax withholding (F)Common Stock54,153USD 0.37USD 20,037SEC filing ↗
2025-12-04Lo StevenAward / grant (A)Common Stock151,351USD 0.00USD 0SEC filing ↗
2025-11-17Watson W. MarkPurchase (P)Common Stock20,000USD 0.41USD 8,200SEC filing ↗
2025-11-17HERON ELAINE JPurchase (P)Common Stock40,000USD 0.40USD 15,936SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerVXRT
CIK0000072444
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeOTC

Data coverage

Local Form 4 history219 transaction lines from 2020-04-28 to 2026-07-16
16 P purchase lines · 63 S sale lines · 140 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.